Health
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics’ first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commissio
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"image","alt":"Crinetics Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Crinetics Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/im.J1fsS6fGk_Ux606V2mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba","width":300,"height":102}},"lazy":false},{"type":"text","content":"PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union","length":98,"tagName":"p"},{"type":"text","content":"Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly","length":156,"tagName":"p"},{"type":"text","content":" Crinetics’ first regulatory approval outside of the U.S., with first launch planned for Germany and Austria","length":107,"tagName":"p"},{"type":"text","content":"SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly.","length":332,"tagName":"p"},{"type":"text","content":"“The European Commission’s decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “This approval represents another exciting milestone for Palsonify as it accelerates to become the new standard in acromegaly care in the U.S., and soon abroad. This is also a notable achievement for Crinetics in pursuit of our vision to become the global leader in endocrinology.”","length":569,"tagName":"p"},{"type":"text","content":"The EC approval is supported by positive results from the pivotal data from the PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, which evaluated PALSONIFY’s safety and efficacy in previously treated and medically untreated adults with acromegaly. Across both trials, PALSONI...